Patients
Tumors
TUMORS, DISEASE
Patients who met the following inclusion criteria were enrolled in the study: (1) aged ≥ 20 years with a documented histological or cytological diagnosis of ccRCC; (2) measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and determined by investigators; (3) had received at least one prior VEGFR-TKI therapy (e.g., sorafenib, sunitinib, axitinib, pazopanib, and tivozanib). Further detailed inclusion and exclusion criteria are described in our previous report [